Proxi Biotech was founded in 2018, based on research conducted at the Statens Serum Institute in Denmark, with a mission to contribute to global health by developing highly needed vaccines overcoming the urgent threat of antimicrobial resistance.
Our research and technology are led by world-class scientists with a strong passion and track record of turning lab scale research into effective vaccine products.
Proxi Biotech's BACTOVAC platform is a versatile toxoid antigen production technology developed to create and advance novel prophylactic and therapeutic vaccines. Our projects are collaborations with private and public partners in the vaccine development space. We focus in developing and bringing vaccine candidates to preclinical proof-of-concept in relevant animal models and early clinical phase.
We has received numerous national and European non-dilutive grants for a total of ca. 820.000 EUR
Copyright 2023 Proxi Biotech ApS All Rights Reserved